Rafei-Shamsabadi DA - Search Results

1

Phosphoinositide acyl chain saturation drives CD8⁺ effector T cell signaling and function.

Edwards-Hicks J, Apostolova P, Buescher JM, Maib H, Stanczak MA, Corrado M, Klein Geltink RI, Maccari ME, Villa M, Carrizo GE, Sanin DE, Baixauli F, Kelly B, Curtis JD, Haessler F, Patterson A, Field CS, Caputa G, Kyle RL, Soballa M, Cha M, Paul H, Martin J, Grzes KM, Flachsmann L, Mitterer M, Zhao L, Winkler F, Rafei-Shamsabadi DA, Meiss F, Bengsch B, Zeiser R, Puleston DJ, O'Sullivan D, Pearce EJ, Pearce EL. Edwards-Hicks J, et al. Among authors: rafei shamsabadi da. Nat Immunol. 2023 Mar;24(3):516-530. doi: 10.1038/s41590-023-01419-y. Epub 2023 Feb 2. Nat Immunol. 2023. PMID: 36732424 Free PMC article.

2

Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone.

Rafei-Shamsabadi D, Lehr S, von Bubnoff D, Meiss F. Rafei-Shamsabadi D, et al. Cancer Immunol Immunother. 2019 Sep;68(9):1417-1428. doi: 10.1007/s00262-019-02377-x. Epub 2019 Aug 17. Cancer Immunol Immunother. 2019. PMID: 31422446 Free PMC article.

3

Case Report: Blurred Vision and Eruptive Nevi - Bilateral Diffuse Uveal Melanocytic Proliferation With Mucocutaneous Involvement in a Lung Cancer Patient.

Rafei-Shamsabadi D, Schneider J, Trefzer L, Technau-Hafsi K, Meiss F, Ness T. Rafei-Shamsabadi D, et al. Front Oncol. 2021 Apr 13;11:658407. doi: 10.3389/fonc.2021.658407. eCollection 2021. Front Oncol. 2021. PMID: 33928039 Free PMC article.

4

Additive Intralesional Interleukin-2 Improves Progression-Free Survival in a Distinct Subgroup of Melanoma Patients with Prior Progression under Immunotherapy.

Rafei-Shamsabadi D, Lehr S, Behrens M, Meiss F. Rafei-Shamsabadi D, et al. Cancers (Basel). 2022 Jan 21;14(3):540. doi: 10.3390/cancers14030540. Cancers (Basel). 2022. PMID: 35158808 Free PMC article.

5

Hemidesmosomal Reactivity and Treatment Recommendations in Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid-A Retrospective, Monocentric Study.

Schauer F, Rafei-Shamsabadi D, Mai S, Mai Y, Izumi K, Meiss F, Kiritsi D. Schauer F, et al. Front Immunol. 2022 Jul 22;13:953546. doi: 10.3389/fimmu.2022.953546. eCollection 2022. Front Immunol. 2022. PMID: 35936009 Free PMC article.

6

Incidence and severity of immune-related hepatitis after dual checkpoint therapy is linked to younger age independent of herpes virus immunity.

Zhang Z, Rafei-Shamsabadi D, Lehr S, Buettner N, Diehl R, Huzly D, Pinato DJ, Thimme R, Meiss F, Bengsch B. Zhang Z, et al. J Transl Med. 2022 Dec 12;20(1):582. doi: 10.1186/s12967-022-03755-3. J Transl Med. 2022. PMID: 36503532 Free PMC article.

7

Variable Outcome of Immunotherapy in Advanced Multiple Cutaneous Squamous Cell Carcinomas in Two Patients with Recessive Dystrophic Epidermolysis Bullosa.

Trefzer L, Hess ME, Scholten L, Technau-Hafsi K, Meiss F, Boerries M, Has C, Rafei-Shamsabadi D. Trefzer L, et al. Acta Derm Venereol. 2023 Jun 20;103:adv4870. doi: 10.2340/actadv.v103.4870. Acta Derm Venereol. 2023. PMID: 37338146 Free PMC article.

8

MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors.

Marschner D, Falk M, Javorniczky NR, Hanke-Müller K, Rawluk J, Schmitt-Graeff A, Simonetta F, Haring E, Dicks S, Ku M, Duquesne S, Aumann K, Rafei-Shamsabadi D, Meiss F, Marschner P, Boerries M, Negrin RS, Duyster J, Zeiser R, Köhler N. Marschner D, et al. JCI Insight. 2020 Mar 26;5(6):e132334. doi: 10.1172/jci.insight.132334. JCI Insight. 2020. PMID: 32125286 Free PMC article.

9

Esophageal carcinoma in severe recessive dystrophic epidermolysis bullosa-an underestimated complication?

Schwieger-Briel A, Trefzer L, Schumann H, Reimer-Taschenbrecker A, Rafei-Shamsabadi D, Meiss F, Has C. Schwieger-Briel A, et al. J Eur Acad Dermatol Venereol. 2022 Apr;36(4):e293-e295. doi: 10.1111/jdv.17826. Epub 2021 Dec 2. J Eur Acad Dermatol Venereol. 2022. PMID: 34807476 No abstract available.

10

Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma.

Braune J, Keller L, Schiller F, Graf E, Rafei-Shamsabadi D, Wehrle J, Follo M, Philipp U, Hussung S, Pfeifer D, Mix M, Duyster J, Fritsch R, von Bubnoff D, Meiss F, von Bubnoff N. Braune J, et al. JCO Precis Oncol. 2020 Nov;4:20-31. doi: 10.1200/PO.19.00174. JCO Precis Oncol. 2020. PMID: 35050727

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page